Opinion: Pharma companies need extra anti-corruption vigilance during a pandemic
Companies have made important efforts over the past two decades to combat the problem of transnational corruption. What was once a relatively obscure regulatory niche has become a major concern for multinational corporations worldwide.
The emergence and spread of Covid-19 has exacerbated the risk of transnational corruption for most industries. But given the extraordinary pressure the pandemic has placed on the health care and life sciences industries to quickly develop and deliver solutions, these companies face a heightened risk. The pharmaceutical industry has increasingly taken proactive steps to guard against transnational corruption, but to address the amplified scope of the risk, industry leaders will need to recalibrate the way they prioritize and address it.
